The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. The method comprises treating skin with P. acnes phage-derived endolysins and nucleic acid molecules encoding the same C in combination with selective essential oils.

The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. The method comprises treating skin with P. acnes phage-derived endolysins and nucleic acid molecules encoding the same C in combination with selective essential oils.

The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. The method comprises treating skin with P. acnes phage-derived endolysins and nucleic acid molecules encoding the same C in combination with selective essential oils.

The present invention relates in general to the field of compositions and methods for using N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) for treating cystinosis. This present invention also relates to the general field of using NAC, NACA or diNACA to treat ophthalmic, ocular or corneal effects of cystinosis. This present invention also relates to the general field of using NAC, NACA, diNACA, cysteamine (or cysteamine salts, e.g., the hydrochloride salt or other salts) or any other cystine-depleting agent for treating ophthalmic, ocular or corneal effects of cystinosis by administration in an ophthalmic or ocular insert.

The present invention relates in general to the field of compositions and methods for using N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) for treating cystinosis. This present invention also relates to the general field of using NAC, NACA or diNACA to treat ophthalmic, ocular or corneal effects of cystinosis. This present invention also relates to the general field of using NAC, NACA, diNACA, cysteamine (or cysteamine salts, e.g., the hydrochloride salt or other salts) or any other cystine-depleting agent for treating ophthalmic, ocular or corneal effects of cystinosis by administration in an ophthalmic or ocular insert.

Pharmaceutical compositions having enhanced active component permeation properties are described.

Pharmaceutical compositions having enhanced active component permeation properties are described.

Novel compositions and systems for closure of wounds with antimicrobial effectiveness are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is also directed to a novel platinum catalyst for use in such compositions. The catalyst provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.